<DOC>
	<DOCNO>NCT02565628</DOCNO>
	<brief_summary>This study design assess safety , tolerability pharmacokinetic data multiple dos PF-06669571 subject idiopathic Parkinson 's disease . In addition , study ass whether PF-06669571 able demonstrate superior efficacy compare placebo treatment motor symptom idiopathic Parkinson 's disease .</brief_summary>
	<brief_title>PF-06669571 In Subjects With Idiopathic Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Subjects must clinical diagnosis idiopathic Parkinson 's disease presence least 2 3 cardinal characteristic ( tremor , rigidity and/or bradykinesia ) . Must Hoehn &amp; Yahr Stage IIIII inclusive experience motor fluctuation form endofdose wear morning hour early morning akinesia . Subjects able recognize `` wear '' symptom verify usually improve next dose Parkinson 's disease medication . Subjects able recognize druginduced dyskinesias verify whether troublesome . History clinical feature consistent atypical parkinsonian syndrome , ( example : ataxia , dystonia , clinically significant orthostatic hypotension .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>